Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Gray Matter | 2 | 2018 | 150 | 1.31 | Why? |
| Language Development Disorders | 2 | 2018 | 10 | 0.95 | Why? |
| Speech Sound Disorder | 2 | 2018 | 6 | 0.95 | Why? |
| Broca Area | 1 | 2018 | 1 | 0.78 | Why? |
| Auditory Cortex | 1 | 2018 | 2 | 0.78 | Why? |
| Mental Navigation Tests | 1 | 2018 | 1 | 0.76 | Why? |
| Amygdala | 1 | 2018 | 42 | 0.76 | Why? |
| Corpus Callosum | 2 | 2018 | 182 | 0.74 | Why? |
| Proteome | 5 | 2021 | 1812 | 0.69 | Why? |
| Cerebellum | 1 | 2017 | 119 | 0.64 | Why? |
| Malaria, Falciparum | 2 | 2019 | 377 | 0.61 | Why? |
| Hippocampus | 1 | 2017 | 237 | 0.58 | Why? |
| Neuroimaging | 1 | 2018 | 1106 | 0.43 | Why? |
| Dexamethasone | 1 | 2021 | 2055 | 0.40 | Why? |
| Magnetic Resonance Imaging | 7 | 2019 | 6551 | 0.34 | Why? |
| Organ Size | 2 | 2018 | 384 | 0.33 | Why? |
| Proteomics | 4 | 2021 | 2481 | 0.32 | Why? |
| Aging | 2 | 2018 | 3581 | 0.29 | Why? |
| Antimalarials | 1 | 2017 | 2505 | 0.27 | Why? |
| Kinetics | 3 | 2021 | 3238 | 0.27 | Why? |
| Berlin | 2 | 2021 | 283 | 0.25 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.25 | Why? |
| Image Processing, Computer-Assisted | 4 | 2018 | 1383 | 0.24 | Why? |
| Germany | 6 | 2021 | 9196 | 0.22 | Why? |
| Receptors, CCR1 | 1 | 2020 | 49 | 0.22 | Why? |
| Respiratory System | 4 | 2021 | 3213 | 0.22 | Why? |
| Chemokine CCL4 | 1 | 2020 | 71 | 0.21 | Why? |
| Chemokine CCL3 | 1 | 2020 | 103 | 0.21 | Why? |
| Brain | 4 | 2018 | 5133 | 0.21 | Why? |
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2021 | 156 | 0.20 | Why? |
| Registries | 1 | 2020 | 12327 | 0.20 | Why? |
| Enzyme Activation | 1 | 2021 | 425 | 0.20 | Why? |
| Sex Characteristics | 2 | 2018 | 1120 | 0.20 | Why? |
| Myelopoiesis | 1 | 2020 | 116 | 0.20 | Why? |
| Antibodies, Viral | 8 | 2021 | 51949 | 0.19 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.19 | Why? |
| Spatial Learning | 1 | 2018 | 7 | 0.19 | Why? |
| Capillary Permeability | 1 | 2021 | 277 | 0.19 | Why? |
| Electric Impedance | 1 | 2021 | 283 | 0.18 | Why? |
| Rejuvenation | 1 | 2018 | 41 | 0.18 | Why? |
| Endostatins | 1 | 2017 | 4 | 0.18 | Why? |
| Angiostatins | 1 | 2017 | 5 | 0.18 | Why? |
| Praziquantel | 1 | 2017 | 44 | 0.17 | Why? |
| Toll-Like Receptor 8 | 1 | 2018 | 102 | 0.17 | Why? |
| Progesterone | 1 | 2018 | 106 | 0.17 | Why? |
| Intracranial Arteriosclerosis | 1 | 2017 | 46 | 0.17 | Why? |
| Blood Gas Analysis | 1 | 2021 | 893 | 0.17 | Why? |
| Endothelium | 1 | 2021 | 460 | 0.17 | Why? |
| Histoplasmosis | 1 | 2018 | 83 | 0.17 | Why? |
| Oral Ulcer | 1 | 2018 | 70 | 0.17 | Why? |
| Cooking | 1 | 2018 | 144 | 0.17 | Why? |
| Atrophy | 1 | 2017 | 192 | 0.17 | Why? |
| Schistosomiasis | 1 | 2017 | 59 | 0.16 | Why? |
| Anthelmintics | 1 | 2017 | 104 | 0.16 | Why? |
| Estradiol | 1 | 2018 | 250 | 0.16 | Why? |
| Blood Proteins | 1 | 2020 | 551 | 0.16 | Why? |
| Immunogenicity, Vaccine | 2 | 2021 | 4624 | 0.15 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2021 | 4545 | 0.15 | Why? |
| Single-Cell Analysis | 3 | 2020 | 2450 | 0.15 | Why? |
| Blood Cell Count | 1 | 2021 | 1101 | 0.15 | Why? |
| Immunoglobulin A | 3 | 2021 | 3567 | 0.14 | Why? |
| Myeloid Cells | 1 | 2020 | 808 | 0.14 | Why? |
| Tandem Mass Spectrometry | 1 | 2021 | 1031 | 0.14 | Why? |
| Young Adult | 12 | 2021 | 93724 | 0.14 | Why? |
| Age Factors | 6 | 2021 | 21039 | 0.14 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2018 | 497 | 0.14 | Why? |
| Microbial Viability | 1 | 2018 | 406 | 0.13 | Why? |
| Neovascularization, Pathologic | 1 | 2017 | 305 | 0.13 | Why? |
| Adult | 21 | 2021 | 244371 | 0.13 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.13 | Why? |
| Viral Load | 4 | 2021 | 15850 | 0.13 | Why? |
| Aged | 19 | 2021 | 215776 | 0.13 | Why? |
| Humans | 39 | 2021 | 930598 | 0.12 | Why? |
| Sex Factors | 3 | 2021 | 11014 | 0.12 | Why? |
| Male | 26 | 2021 | 367725 | 0.12 | Why? |
| Vaccines, Attenuated | 1 | 2018 | 952 | 0.12 | Why? |
| Observational Studies as Topic | 1 | 2020 | 1887 | 0.12 | Why? |
| Biological Specimen Banks | 1 | 2020 | 1142 | 0.12 | Why? |
| Female | 26 | 2021 | 380317 | 0.12 | Why? |
| Middle Aged | 21 | 2021 | 270681 | 0.12 | Why? |
| Lymphocyte Activation | 2 | 2020 | 2742 | 0.11 | Why? |
| Postpartum Period | 1 | 2018 | 936 | 0.11 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.11 | Why? |
| Plasma | 1 | 2021 | 1809 | 0.11 | Why? |
| Communicable Diseases, Imported | 1 | 2019 | 843 | 0.11 | Why? |
| Endothelial Cells | 1 | 2021 | 2048 | 0.10 | Why? |
| Vaccination | 5 | 2021 | 19050 | 0.10 | Why? |
| Dengue Virus | 1 | 2017 | 910 | 0.10 | Why? |
| Sentinel Surveillance | 1 | 2017 | 1093 | 0.10 | Why? |
| Hypertension | 2 | 2021 | 8895 | 0.09 | Why? |
| Phenotype | 1 | 2020 | 4037 | 0.09 | Why? |
| Immunoglobulin G | 6 | 2021 | 21571 | 0.09 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.09 | Why? |
| Adolescent | 8 | 2021 | 86841 | 0.09 | Why? |
| Epitopes | 1 | 2021 | 4113 | 0.09 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.09 | Why? |
| Virus Shedding | 2 | 2021 | 5834 | 0.08 | Why? |
| Tuberculosis, Pulmonary | 1 | 2018 | 1171 | 0.08 | Why? |
| Longitudinal Studies | 5 | 2021 | 9893 | 0.08 | Why? |
| Blood Donors | 1 | 2021 | 2956 | 0.08 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
| Brain Diseases | 1 | 2019 | 1463 | 0.08 | Why? |
| Transcriptome | 1 | 2020 | 3466 | 0.08 | Why? |
| T-Lymphocytes | 2 | 2021 | 6670 | 0.08 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.08 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.08 | Why? |
| Europe | 3 | 2017 | 12702 | 0.08 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.07 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.07 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.07 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Machine Learning | 1 | 2021 | 4395 | 0.07 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.07 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.07 | Why? |
| Dengue | 1 | 2017 | 1565 | 0.07 | Why? |
| Inflammation | 3 | 2021 | 13255 | 0.07 | Why? |
| Renal Dialysis | 1 | 2021 | 4358 | 0.07 | Why? |
| Tertiary Care Centers | 1 | 2021 | 8248 | 0.06 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.06 | Why? |
| Cell Differentiation | 2 | 2020 | 1338 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Occludin | 1 | 2021 | 53 | 0.06 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.06 | Why? |
| Saccharomyces cerevisiae Proteins | 1 | 2021 | 66 | 0.06 | Why? |
| Travel | 2 | 2017 | 7220 | 0.05 | Why? |
| CD11 Antigens | 1 | 2020 | 74 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2020 | 8041 | 0.05 | Why? |
| Actins | 1 | 2021 | 108 | 0.05 | Why? |
| Arabidopsis | 1 | 2021 | 88 | 0.05 | Why? |
| Cadherins | 1 | 2021 | 145 | 0.05 | Why? |
| CD3 Complex | 1 | 2021 | 237 | 0.05 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.05 | Why? |
| Spike Glycoprotein, Coronavirus | 5 | 2021 | 37182 | 0.05 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.05 | Why? |
| Immunity | 2 | 2021 | 2651 | 0.05 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.05 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.05 | Why? |
| Saccharomyces cerevisiae | 1 | 2021 | 339 | 0.05 | Why? |
| Maximal Midexpiratory Flow Rate | 1 | 2018 | 15 | 0.05 | Why? |
| Antigen-Antibody Reactions | 1 | 2020 | 616 | 0.05 | Why? |
| Guatemala | 1 | 2018 | 106 | 0.05 | Why? |
| Mice, Inbred C57BL | 2 | 2020 | 5542 | 0.04 | Why? |
| Cell Communication | 1 | 2020 | 396 | 0.04 | Why? |
| HLA-DR Antigens | 1 | 2020 | 563 | 0.04 | Why? |
| Caco-2 Cells | 1 | 2021 | 1236 | 0.04 | Why? |
| Child | 4 | 2021 | 70012 | 0.04 | Why? |
| Tanzania | 1 | 2018 | 294 | 0.04 | Why? |
| Probability | 1 | 2021 | 923 | 0.04 | Why? |
| Itraconazole | 1 | 2018 | 135 | 0.04 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.04 | Why? |
| Immunodominant Epitopes | 1 | 2021 | 813 | 0.04 | Why? |
| Microvessels | 1 | 2021 | 490 | 0.04 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Immunoglobulins | 1 | 2021 | 811 | 0.04 | Why? |
| Americas | 1 | 2017 | 418 | 0.04 | Why? |
| Asia, Southeastern | 1 | 2017 | 390 | 0.04 | Why? |
| Antigens, CD | 1 | 2021 | 984 | 0.04 | Why? |
| Cell Line | 2 | 2021 | 12040 | 0.04 | Why? |
| Forced Expiratory Volume | 1 | 2018 | 632 | 0.04 | Why? |
| Healthy Volunteers | 1 | 2020 | 1444 | 0.03 | Why? |
| Open Reading Frames | 1 | 2021 | 1898 | 0.03 | Why? |
| Coronavirus NL63, Human | 1 | 2020 | 669 | 0.03 | Why? |
| Travel Medicine | 1 | 2017 | 335 | 0.03 | Why? |
| Ischemic Attack, Transient | 1 | 2017 | 439 | 0.03 | Why? |
| Viremia | 1 | 2020 | 1020 | 0.03 | Why? |
| Crystallography, X-Ray | 1 | 2020 | 2689 | 0.03 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.03 | Why? |
| Cricetinae | 1 | 2020 | 3344 | 0.03 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.03 | Why? |
| Africa South of the Sahara | 1 | 2017 | 1335 | 0.03 | Why? |
| Coronavirus OC43, Human | 1 | 2020 | 1157 | 0.03 | Why? |
| Coronavirus 229E, Human | 1 | 2020 | 1241 | 0.03 | Why? |
| Prevalence | 3 | 2019 | 25773 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.03 | Why? |
| Peptide Fragments | 1 | 2021 | 2075 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2021 | 17020 | 0.03 | Why? |
| Immune System | 1 | 2020 | 1479 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.03 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.02 | Why? |
| Long-Term Care | 1 | 2021 | 2047 | 0.02 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.02 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2020 | 2262 | 0.02 | Why? |
| Cells, Cultured | 1 | 2020 | 5835 | 0.02 | Why? |
| Peptidyl-Dipeptidase A | 2 | 2020 | 9659 | 0.02 | Why? |
| Swine | 1 | 2018 | 3352 | 0.02 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2021 | 3444 | 0.02 | Why? |
| Peptides | 1 | 2021 | 2513 | 0.02 | Why? |
| Animals | 4 | 2020 | 78931 | 0.02 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.02 | Why? |
| Epithelial Cells | 1 | 2020 | 3508 | 0.02 | Why? |
| Binding Sites | 1 | 2020 | 6201 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Africa | 1 | 2017 | 2986 | 0.02 | Why? |
| Australia | 1 | 2021 | 6306 | 0.02 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2020 | 4155 | 0.02 | Why? |
| Infant | 2 | 2021 | 30274 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.02 | Why? |
| Child, Preschool | 2 | 2021 | 36283 | 0.02 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Antibody Formation | 1 | 2018 | 4038 | 0.02 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.02 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.02 | Why? |
| Protein Binding | 1 | 2020 | 11430 | 0.02 | Why? |
| Fever | 1 | 2021 | 7795 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.02 | Why? |
| Disease Models, Animal | 1 | 2020 | 10998 | 0.01 | Why? |
| Lung | 2 | 2021 | 31049 | 0.01 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.01 | Why? |
| Mice | 1 | 2020 | 21357 | 0.01 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 13720 | 0.01 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Stroke | 1 | 2017 | 8839 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |